Related Experiment Video

Updated: Feb 22, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.5K

Age-Appropriate Formulations Including Pharmaceutical Excipients in Neonatal Medicines

Karin Kogermann1, Jana Lass2,3, Georgi Nellis4

  • 1Institute of Pharmacy, Faculty of Medicine, University of Tartu, Tartu, Estonia.

Current Pharmaceutical Design
|September 28, 2017
PubMed

Insights

Developing age-appropriate pharmaceutical formulations for neonates is crucial. Novel drug delivery systems aim to reduce medication errors and improve safety and efficacy in neonatal care.

Area of Science:

  • Neonatal Pharmacology
  • Pharmaceutical Sciences
  • Drug Delivery Systems

Background:

  • Neonatal drug formulation presents unique challenges due to developmental immaturity.
  • Extemporaneous compounding is common but lacks standardization, leading to medication errors and safety concerns.

Purpose of the Study:

  • To review challenges in neonatal drug formulation and excipient exposure.
  • To explore novel drug delivery approaches for improved neonatal care.

Main Methods:

  • Literature review of recent formulations and pharmaceutical excipients.

Main Results:

  • Identified issues with age-inappropriate formulations and harmful excipient exposure in neonates.
  • Discussed strategies to minimize excipient risks and challenges in designing neonatal dosage forms.
  • Summarized emerging drug delivery technologies for neonates.

Conclusions:

  • Novel age-appropriate drug delivery systems are needed to enhance medicine quality and reduce neonatal treatment errors.
  • Further research into new technologies, formulations, and excipients, supported by rigorous testing, is essential for safe and effective neonatal drug delivery.
Abstract

Keywords:
Neonatedrug deliveryextemporaneous drug formulationsmedication errorspaediatric dosage formssuboptimal efficacy.

More Related Videos

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.7K
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

38.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
354
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
351
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
197
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
217